These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations. Garay T; Molnár E; Juhász É; László V; Barbai T; Dobos J; Schelch K; Pirker C; Grusch M; Berger W; Tímár J; Hegedűs B Pathol Oncol Res; 2015 Sep; 21(4):957-68. PubMed ID: 25749811 [TBL] [Abstract][Full Text] [Related]
6. Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. Kodach LL; Bos CL; Durán N; Peppelenbosch MP; Ferreira CV; Hardwick JC Carcinogenesis; 2006 Mar; 27(3):508-16. PubMed ID: 16344270 [TBL] [Abstract][Full Text] [Related]
7. Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152. Kim YK; Ahn SK; Lee M Cancer Lett; 2012 Jul; 320(2):215-24. PubMed ID: 22425959 [TBL] [Abstract][Full Text] [Related]
8. Seriniquinones as Therapeutic Leads for Treatment of BRAF and NRAS Mutant Melanomas. Hirata AS; Rezende-Teixeira P; Machado-Neto JA; Jimenez PC; Clair JJ; Fenical W; Costa-Lotufo LV Molecules; 2021 Dec; 26(23):. PubMed ID: 34885944 [TBL] [Abstract][Full Text] [Related]
9. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib. Krayem M; Journe F; Wiedig M; Morandini R; Sales F; Awada A; Ghanem G Eur J Cancer; 2014 May; 50(7):1310-20. PubMed ID: 24559688 [TBL] [Abstract][Full Text] [Related]
10. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Jiang CC; Lai F; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD Clin Cancer Res; 2011 Feb; 17(4):721-30. PubMed ID: 21088259 [TBL] [Abstract][Full Text] [Related]
11. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806 [TBL] [Abstract][Full Text] [Related]
12. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Siwak DR; Shishodia S; Aggarwal BB; Kurzrock R Cancer; 2005 Aug; 104(4):879-90. PubMed ID: 16007726 [TBL] [Abstract][Full Text] [Related]
13. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033 [TBL] [Abstract][Full Text] [Related]
14. BRAF V600E-dependent role of autophagy in uveal melanoma. Zhao Y; Wang W; Min I; Wyrwas B; Moore M; Zarnegar R; Fahey TJ J Cancer Res Clin Oncol; 2017 Mar; 143(3):447-455. PubMed ID: 27928645 [TBL] [Abstract][Full Text] [Related]
15. Violacein, an indole-derived purple-colored natural pigment produced by Janthinobacterium lividum, inhibits the growth of head and neck carcinoma cell lines both in vitro and in vivo. Masuelli L; Pantanella F; La Regina G; Benvenuto M; Fantini M; Mattera R; Di Stefano E; Mattei M; Silvestri R; Schippa S; Manzari V; Modesti A; Bei R Tumour Biol; 2016 Mar; 37(3):3705-17. PubMed ID: 26462840 [TBL] [Abstract][Full Text] [Related]
16. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506 [TBL] [Abstract][Full Text] [Related]
17. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK. Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225 [TBL] [Abstract][Full Text] [Related]
18. Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis. Fritsche-Guenther R; Witzel F; Kempa S; Brummer T; Sers C; Blüthgen N Oncotarget; 2016 Feb; 7(7):7960-9. PubMed ID: 26799289 [TBL] [Abstract][Full Text] [Related]